176 related articles for article (PubMed ID: 38189812)
1. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
[TBL] [Abstract][Full Text] [Related]
3. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study.
Bannangkoon K; Hongsakul K; Tubtawee T; Ina N; Chichareon P
Sci Rep; 2023 Mar; 13(1):3978. PubMed ID: 36894658
[TBL] [Abstract][Full Text] [Related]
4. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization.
Roth G; Teyssier Y; Benhamou M; Abousalihac M; Caruso S; Sengel C; Seror O; Ghelfi J; Seigneurin A; Ganne-Carrie N; Gigante E; Blaise L; Sutter O; Decaens T; Nault JC
World J Gastroenterol; 2022 Sep; 28(36):5324-5337. PubMed ID: 36185630
[TBL] [Abstract][Full Text] [Related]
6. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
[TBL] [Abstract][Full Text] [Related]
8. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
Shin BS; Park MH; Jeon GS
Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
[TBL] [Abstract][Full Text] [Related]
10. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.
Oliveri RS; Wetterslev J; Gluud C
Cochrane Database Syst Rev; 2011 Mar; (3):CD004787. PubMed ID: 21412886
[TBL] [Abstract][Full Text] [Related]
11. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.
Xie ZB; Ma L; Wang XB; Bai T; Ye JZ; Zhong JH; Li LQ
Tumour Biol; 2014 Sep; 35(9):8451-9. PubMed ID: 25038916
[TBL] [Abstract][Full Text] [Related]
12. Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization.
Masetti C; Pugliese N; Lofino L; Colapietro F; Ceriani R; Lleo A; Poretti D; Pedicini V; De Nicola S; Torzilli G; Rimassa L; Aghemo A; Lanza E
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615062
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
14. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of sarcopenic visceral obesity in hepatocellular carcinoma treated with TACE.
Li Y; Hou J; Chen R
Medicine (Baltimore); 2023 Jul; 102(27):e34292. PubMed ID: 37417609
[TBL] [Abstract][Full Text] [Related]
16. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE.
Lim J; Kim KW; Ko Y; Jang IY; Lee YS; Chung YH; Lee HC; Lim YS; Kim KM; Shim JH; Choi J; Lee D
BMC Cancer; 2021 Oct; 21(1):1164. PubMed ID: 34715813
[TBL] [Abstract][Full Text] [Related]
17. The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.
Tseeleesuren D; Hsiao HH; Kant R; Huang YC; Tu HP; Lai CC; Huang SF; Yen CH
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208536
[No Abstract] [Full Text] [Related]
18. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
20. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses.
Cheng X; Sun P; Hu QG; Song ZF; Xiong J; Zheng QC
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1159-70. PubMed ID: 24752339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
